MyFinsight
Home
Blog
About
Maturities of short-term
investments
$25,000K
(25.00%↑ Y/Y)
Proceeds from the espp
purchase
$236K
(31.11%↑ Y/Y)
Net cash and cash
equivalents provided by...
$24,999K
(129.94%↑ Y/Y)
Net cash and cash
equivalents provided by...
$220K
(-99.78%↓ Y/Y)
Canceled cashflow
$1K
Canceled cashflow
$16K
Net increase
(decrease) in cash, cash...
$269K
(101.47%↑ Y/Y)
Canceled cashflow
$24,950K
Purchases of property and
equipment
-$1K
(99.34%↑ Y/Y)
Accrued liabilities
$6,707K
(300.09%↑ Y/Y)
Stock-based compensation
including espp
$1,364K
(-35.63%↓ Y/Y)
Other assets
-$620K
(-226.32%↓ Y/Y)
Non cash lease
expense
$473K
(-47.73%↓ Y/Y)
Depreciation expense
$255K
(-43.71%↓ Y/Y)
Payments on finance lease
$16K
(1500.00%↑ Y/Y)
Net cash and cash
equivalents used in...
-$24,950K
(31.48%↑ Y/Y)
Canceled cashflow
$9,419K
Accounts receivable
$27,778K
Change in fair value of
2023 common warrants
-$2,976K
(95.29%↑ Y/Y)
Net (loss) income,
as reported
-$1,504K
(-105.52%↓ Y/Y)
Accounts payable
-$1,208K
(-190.96%↓ Y/Y)
Operating lease
liabilities
-$831K
(44.56%↑ Y/Y)
Accretion of discount on
investments
$72K
(-93.04%↓ Y/Y)
Back
Back
Cash Flow
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)
source: myfinsight.com